Vimco vet.
Active substance
ATC code
Species
Ewes and adult female goats.
Indications
For active immunisation of healthy ewes in flocks with recurring mastitis problems, to reduce the incidence of sub-clinical mastitis (reduction of udder lesions, somatic cell count and S. aureus count) caused by Staphylococcus aureus.
For active immunisation of healthy female goats in herds with recurring mastitis problems, to reduce the incidence of sub-clinical mastitis caused by Staphylococcus aureus and/or Coagulase-Negative Staphylococci; when clinical mastitis caused by Coagulase-Negative Staphylococci* however occurs, the severity of clinical signs (udder and milk aspect) is reduced.
(*Determination of the CNS species has not been performed)
The onset of immunity in ewes is 6 weeks.
The onset of immunity in goats has not been established (see section 5). The duration of immunity in ewes and goats has not been established.
Dose to be administered and administration route
Intramuscular use.
Allow the vaccine to reach a temperature of +15 ºC to +25 ºC before administration.
Shake before use.
Minimum age at vaccination: 8 months.
Administer one dose (2 ml) by deep intramuscular injection in the neck muscles at 5 weeks before the expected parturition date and 3 weeks after the first dose, administer a second dose.
The basic vaccination scheme is to be repeated prior to each lactation.
Adverse reactions
- Slight swelling at the injection site of less than 2 cm in diameter, which disappears within 12 days at most, occurred very commonly during clinical studies.
- Swelling at the injection site higher than 5 cm in diameter, which resolves within 3 days at most, occurred commonly during clinical studies.
- Transient increase in body temperature of up to 1.8 ºC occurred commonly between the first 4 hours and 3 days after injection during clinical studies, which spontaneously resolves within some days without compromising animal health status.
- Anaphylactic-type reactions, which might be life-threatening and/or cause abortion occurred very rarely based on post-authorisation pharmacovigilance reporting. Under these circumstances, appropriate and rapid symptomatic treatment should be administered.
- Mild apathy, anorexia and/or recumbency occurred very rarely after administration of the vaccine based on post-authorisation pharmacovigilance reporting.
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
